Skip to main content
Clinical Trials/DRKS00013501
DRKS00013501
Not yet recruiting
未知

Metabolic and neurovascular brain plasticity in amyloid-positive older people with metabolic risk factors - EnergI

Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.0 sites300 target enrollmentDecember 15, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Metabolic risk factors defined by ATP-III-criteriaAmyloid deposition as indication of preclinical Alzheimer’s disease
Sponsor
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.
Enrollment
300
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 15, 2017
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Body Mass Index \= 25 to max. 40 kg / m2
  • \- Presence of at least one metabolic risk factor (according to ATP III criteria (National Cholesterol Education Program (NCEP): Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report), 2002 )
  • Abdominal obesity, determined by a waist circumference of over 102 cm in men or over 88 cm in women
  • Fasting triglycerides greater than 150 mg/dl (\> 1\.7 mmol/l), or already initiated therapy to reduce triglycerides
  • HDL cholesterol \= 40 mg/dl (\<1\.05 mmol/l) in men or \<50 mg/dl (1\.25 mmol/l) in women
  • Blood pressure of 130/85 mmHg or higher, or already initiated therapy to reduce hypertension
  • Fasting glucose \= 110 mg/dl (5\.6 mmol/l)
  • \- Written declaration of consent for PET measurements with \[18F]\-FDG and \[18F]\-Florbetaben
  • \- Preserved legal capacity of the subjects at the time of each examination

Exclusion Criteria

  • \- Coronary heart disease in all manifestations
  • \- Cardiomyopathies
  • \- Supraventricular and ventricular arrhythmias
  • \- Clinically relevant cardiac defects
  • \- Blood pressure above 140/90 mmHg
  • \- heart insufficiency \> stage IIb according to NYHA
  • \- Severe chronic obstructive pulmonary disease (COPD), bronchial asthma
  • \- Resting bradycardia (below 45 bpm)
  • \- Relevant orthopedic diseases
  • \- Serious internal diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials